EntreMed Incorporated

EntreMed, Inc. is a clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them. EntreMed is focused on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. EntreMed’s goal is to develop and commercialize therapeutics based on the Company’s scientific expertise in angiogenesis, cell cycle regulation and inflammation -- processes vital to the progression of cancer and other diseases. The Company’s three clinical product candidates are based on these mechanisms. The Company’s expertise has also led to the identification of new molecules, including new chemical entities derived from 2ME2, as well as new chemical entities associated with multi-kinase inhibition and HDAC inhibition, important targets in the treatment of oncology. Panzem® (2-methoxyestradiol or 2ME2), one of the Company’s two lead drug candidates, is currently being tested as a cancer therapeutic in five Phase 2 clinical trials, and has been granted U.S. Food and Drug Administration (FDA) Orphan Drug designation in three cancer indications, including glioblastoma multiforme (GBM), multiple myeloma, and ovarian cancer. MKC-1, a novel cell cycle inhibitor, is also in Phase 2 clinical trials for cancer. In May 2006, the Company commenced clinical studies with its third clinical-stage compound, ENMD-1198, in patients with advanced cancer. EntreMed is developing compounds that have broad therapeutic and commercial potential in oncology. In order to further advance its commercial objectives, EntreMed may seek strategic alliances, licensing relationships and co-development partnerships with other companies to develop compounds for both oncology and non-oncology therapeutic areas.

Contact Details: 9640 Medical Center Drive Rockville MD 20850 United States of America Tel: 240.864.2600 Fax: 240.864.2601 Email: ginnyd@entremed.com WWW: www.entremed.com/

Loading...

Recent Publications by EntreMed Incorporated:
Significant antitumor activity in vivo following treatment with the microtubule agent ENMD-1198. Clinical studies using the microtubule-targeting agent 2-methoxyestradiol...	23rd August, 2008	EntreMed, Inc., 9640 Medical Center Drive, Rockville, MD 20850, USA.	Mol Cancer Ther. 2008 Jun;7(6):1472-82. DOI Direct Link
Oxidative metabolism of murine macrophages. This unit describes two simple and straightforward microassays that can be...	6th June, 2008	EntreMed, Inc., Rockville, Maryland, USA.	Curr Protoc Immunol. 2001 May;Chapter 14:Unit 14.5. DOI Direct Link
Activation of murine macrophages. Macrophages can act as potent effector cells of the immune response....	6th June, 2008	EntreMed, Inc., Rockville, Maryland, USA.	Curr Protoc Immunol. 2001 May;Chapter 14:Unit 14.4. DOI Direct Link
Isolation of murine macrophages. Macrophages isolated from murine peritoneal cavity, bone marrow, and...	6th June, 2008	EntreMed, Inc., Rockville, Maryland, USA.	Curr Protoc Immunol. 2001 May;Chapter 14:Unit 14.1. DOI Direct Link
Synthesis and structure-activity relationships of 16-modified analogs of 2-methoxyestradiol. A series of 16-modified 2-methoxyestradiol analogs were synthesized and...	20th February, 2008	EntreMed, Inc., Discovery Research Department, 9640 Medical Center Drive,	Bioorg Med Chem. 2007 Dec 15;15(24):7524-37. Epub 2007 Sep 14. DOI Direct Link
→View more EntreMed Incorporated research publications.

BioNews Results for EntreMed Incorporated:
Cancer - EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program	NewsRX:  Aug 27 2008 2:52PM Matching: entremed
EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program	Macro World Investor:  Aug 21 2008 10:35PM Matching: entremed
EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program	Evergreen Investments:  Aug 21 2008 10:19PM Matching: entremed
BioPartnering Europe 2008 Conference	SmartBrief:  Aug 18 2008 9:52PM Matching: entremed
BioPartnering Europe 2008 Conference	Pharma Live:  Aug 18 2008 3:26PM Matching: entremed
Promote your company here: BioNewsCast - Press Release Distribution	→View more EntreMed Incorporated news.

EntreMed Incorporated Patents:
US Patent No.	Title
7371741	Estradiol derivatives and pharmaceutical compositions using same
6224902	Vaccines against sterols
6201104	Angiogenesis--inhibiting protein binding peptides and proteins and methods of use
6090617	Flow electroporation chamber with electrodes having a crystalline metal nitride coating
6074605	Flow electroporation chamber and method
→View more EntreMed Incorporated patents.

EntreMed Incorporated (ENMD) Financial information Links from Barchart
ENMD Quote from from Barchart.com
ENMD Chart from from Barchart.com
ENMD Profile from from Barchart.com
ENMD Opinion from from Barchart.com
→View more EntreMed Incorporated finance information.

Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.

This page has been viewed 271 times since April 2007, the link to the organisation's website has been followed 48 times

Recent Search Terms used to find this page: @entremed.com | 3 3-diarylacrylonitriles | entremed bioorg med chem | med chem entremed | med chem entremed | entremed.com | entremed.com | EntreMed Incorporated | Entremed Incorporated | A Study to Determine the Antitumor Activity and Evaluate the Safety of MKC-1 | .

Search for more companies in Rockville

Search for more companies in MD

This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.
BioPortfolio search results for EntreMed Incorporated